Survodutide and mazdutide target the same two receptors — the GLP-1 receptor and the glucagon receptor — but they were built from different starting points. Survodutide (development code BI 456906) is an engineered acylated scaffold designed from scratch to hit a chosen potency ratio at the two receptors; mazdutide (IBI362, LY3305677) is a stabilised analog of oxyntomodulin, the proglucagon-derived hormone that already activates both receptors in nature. In a survodutide vs mazdutide comparison the discriminating question is therefore not "which receptors" but "which receptor balance, and does a designed ratio behave differently from the one evolution supplied?"
Both are supplied here as lyophilized powder in 5 mg, 10 mg and 20 mg vials with lot-matched HPLC certificates: survodutide and mazdutide, both listed under GLP-1 and incretin peptides. Both are research chemicals for in-vitro and preclinical laboratory work only — not medicines, and not for human or veterinary use.
Survodutide vs mazdutide at a glance
| Attribute | Survodutide | Mazdutide |
|---|---|---|
| Development codes in the literature | BI 456906 | IBI362, LY3305677 |
| Design lineage | Engineered de-novo peptide scaffold | Analog of native oxyntomodulin |
| Receptor targets | Glucagon receptor (GCGR) and GLP-1 receptor | GLP-1 receptor and glucagon receptor (GCGR) |
| Reported receptor emphasis | Comparatively strong glucagon-receptor arm relative to single-incretin agonists | Oxyntomodulin-like ratio, generally described as GLP-1-leaning |
| Class | Acylated dual agonist peptide | Acylated dual agonist peptide |
| Half-life strategy | Fatty-acid side chain supporting reversible albumin binding | Fatty-acid side chain plus stabilising substitutions against DPP-4 cleavage |
| CAS number | 2360883-97-4 | 2259884-42-1 |
| Physical form | Lyophilized powder, sealed glass vial | Lyophilized powder, sealed glass vial |
| Research sizes stocked | 5 mg, 10 mg, 20 mg | 5 mg, 10 mg, 20 mg |
| Purity | ≥99% HPLC, MS identity, lot-matched COA | ≥99% HPLC, MS identity, lot-matched COA |
| Typical research question | What does adding glucagon-receptor drive do to a GLP-1 response? | Does an oxyntomodulin-derived ratio differ from a designed one? |
| Common comparators | Retatrutide, tirzepatide, semaglutide | Survodutide, retatrutide, semaglutide |
Why a glucagon arm is added at all
Single-agonist incretin analogs act on one axis: GLP-1 receptor engagement is associated in the literature with reduced food intake, slowed gastric emptying and glucose-dependent insulin secretion. Adding glucagon receptor activity introduces a second and quite different set of endpoints — hepatic substrate handling, ketogenesis, lipid mobilisation and, in rodent indirect-calorimetry work, increased energy expenditure. The design logic reported for both molecules is that the incretin arm supplies intake suppression while the glucagon arm supplies an expenditure and hepatic component, with the incretin arm also offsetting the glycaemic consequence of glucagon receptor stimulation.
That is the shared premise. Where the two molecules separate is in how the balance was arrived at. Survodutide is a designed dual agonist: the sequence was optimised specifically to land at a target potency ratio, so the ratio is a deliberate parameter. Mazdutide keeps the oxyntomodulin template, which means the ratio is inherited rather than chosen, then modified only enough to survive circulation. For a laboratory building a structure–activity series, that difference is the experiment.
Structure and stabilisation chemistry
Native oxyntomodulin is a 37-residue proglucagon product that activates both receptors but is cleared within minutes, largely through dipeptidyl peptidase-4 cleavage and renal filtration. Mazdutide carries substitutions that blunt that cleavage plus a fatty-acid side chain enabling reversible albumin binding, which is the same lipidation strategy used across the modern incretin class. Survodutide uses the same broad approach — acylation for albumin association — on a sequence that is not a direct copy of any single native hormone.
Practically, the acyl chain matters more to bench handling than the sequence difference does. Both peptides are amphipathic and both carry a lipophilic tail, so both behave like surfactant-adjacent molecules in dilute aqueous solution: adsorption to glass and polypropylene at low concentration is the most common source of unexplained potency loss in cell assays with either compound. Neither should be assumed interchangeable with the other's stock-preparation protocol without a concentration check.
What the research record looks like for each
The published human evidence for both molecules sits with their sponsors' investigational clinical programmes, which are regulated activities involving pharmaceutical-grade drug product under medical supervision. That evidence does not transfer to research-grade material bought as a reagent, and nothing on this page should be read as suggesting it does.
What is directly relevant to a reagent user is the preclinical and in-vitro layer. For both compounds that layer typically comprises cyclic-AMP accumulation assays in cells transfected separately with human GCGR and human GLP-1R, to establish the potency ratio; beta-arrestin recruitment assays, where the incretin field has reported meaningful differences in bias between analogs; hepatocyte and adipocyte systems, where glucagon-driven readouts such as glucose output, ketone production and lipid content can be separated from anything intake-related; and rodent energy-balance studies pairing food-intake measurement with indirect calorimetry. Survodutide has additionally appeared in preclinical work oriented toward hepatic endpoints, consistent with its glucagon emphasis, and mazdutide in work framed around the oxyntomodulin lineage specifically.
Which to choose for which research question
Choose survodutide when the glucagon arm is the variable
If the design asks how far a glucagon-receptor contribution can be pushed before glycaemic or hepatic readouts change direction, survodutide is the more informative probe, because its glucagon arm is the feature it was engineered around. It is also the natural comparator when a triple agonist such as retatrutide is under study and the question is what the added GIP component contributes on top of an existing GLP-1 plus glucagon baseline — survodutide isolates that baseline.
Choose mazdutide when the native template is the point
If the hypothesis concerns oxyntomodulin biology — whether the endogenous receptor ratio is functionally distinct, or whether a stabilised native peptide reproduces effects reported for designed scaffolds — mazdutide is the appropriate tool because it preserves that template. It is also the better reference when a laboratory is characterising its own oxyntomodulin-derived constructs and needs a well-defined comparator from the same structural family.
Run both when the ratio itself is the question
The most common study design in practice uses both. Two dual agonists with the same receptor pair and different balances form a two-point series; adding a pure GLP-1 agonist such as semaglutide as the zero-glucagon anchor makes it three. That arrangement lets a group attribute an effect to glucagon-receptor engagement rather than to the incretin component, which a single-compound experiment cannot do. Both are stocked in matching 5, 10 and 20 mg sizes, which makes molar-matched parallel preparation straightforward.
Handling, reconstitution and storage differences
The two behave similarly enough that one laboratory protocol usually covers both, with the caveats below. Sealed lyophilized vials are kept frozen for long-term holding and are brought to room temperature before opening so that atmospheric moisture does not condense onto cold powder. Reconstitution is performed by directing the diluent stream down the vial wall rather than onto the cake, then leaving the vial to dissolve without shaking — agitation drives foaming and interfacial denaturation in acylated peptides.
Concentration is a laboratory calculation, not a recommendation for use: a 10 mg vial reconstituted with 2 mL of diluent gives 5 mg/mL, and 0.1 mL of that solution contains 500 mcg of peptide. The same arithmetic applies to both compounds, but the labelled vial mass includes counter-ion and residual water in each case, so net peptide is lower than the label suggests and the offset is not necessarily identical between two different molecules. Groups comparing the two quantitatively should anchor to a measured concentration rather than the label. See our reconstitution guide and storage guide for the full lab procedure, and prepare single-use aliquots so neither stock is subjected to repeated freezing and thawing.
Purity, identity and COA checks
Request the lot-matched certificate for each vial and read three things: an HPLC purity figure with a visible chromatogram rather than a bare number, a mass-spectrometric result consistent with the expected mass of the acylated peptide, and a lot number that matches the label on the vial in hand. For acylated dual agonists the most instructive impurity signals are late-eluting peaks, which can indicate incompletely removed acylation by-products, and any evidence of des-acyl species, which retain sequence but lose the albumin-binding behaviour that defines the molecule's exposure profile. Our guide to reading a COA covers what each section of the document should contain.
Regulatory framing
Survodutide and mazdutide are both investigational molecules. Neither is an approved medicine in the United States, and the material supplied here is a research chemical labelled for laboratory use only. Clinical data reported for either compound belong to sponsor-run trials using pharmaceutical product under supervision, and are cited on this page only to describe the state of the published record. Nothing here is a protocol for human or veterinary use, and neither compound is offered for that purpose. For broader context on how these molecules sit within the metabolic research landscape, see our weight-management research overview.